Arrowhead CFO Ken Myszkowski to retire May 13; Daniel Apel named new CFO

ARROWHEAD PHARMACEUTICALS, INC.

Ken Myszkowski will retire as CFO effective May 13, 2025, after 16 years; no disagreement cited.
Daniel Apel, former Global Head of FP&A at Walgreens Boots Alliance and Bayer US CFO, appointed CFO same date.
Apel receives $575K base salary, 45% target bonus, 100K RSUs vesting over 4 years, and up to $200K relocation.
Myszkowski will serve as adviser through Jan 31, 2026, at $200K annual salary with continued benefits and equity vesting.
CEO cites transition to commercial stage with planned plozasiran launch pending regulatory review.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ken Myszkowski

Chief Financial Officer

ARWR · ARROWHEAD PHARMACEUTICALS, INC.

Effective: 2025-05-13
Successor: Daniel Apel
Filed: April 15, 2025, 7:59 PM ET

Ken Myszkowski notified Arrowhead Pharmaceuticals, Inc. (the “Company”) of his decision to retire as Chief Financial Officer of the Company, effective as of May 13, 2025

Appointed

Daniel Apel

Chief Financial Officer

ARWR · ARROWHEAD PHARMACEUTICALS, INC.

Effective: 2025-05-13
Filed: April 15, 2025, 7:59 PM ET

the Company determined that it would appoint Daniel Apel to serve as Chief Financial Officer of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Ken Myszkowski departed as Chief Financial Officer at ARROWHEAD PHARMACEUTICALS, INC..

Action: retire
Role: Chief Financial Officer

Exact text from the filing

Ken Myszkowski notified Arrowhead Pharmaceuticals, Inc. (the “Company”) of his decision to retire as Chief Financial Officer of the Company, effective as of May 13, 2025

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel Apel was appointed as Chief Financial Officer at ARROWHEAD PHARMACEUTICALS, INC..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

the Company determined that it would appoint Daniel Apel to serve as Chief Financial Officer of the Company

View on SEC.gov

ARROWHEAD PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-25-017844

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.